Browsing by Keyword : Infliximab

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 1 to 17 of 17

Pub YearTitleAJOU Author(s)
2023Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview서창희
2017Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab김현아, 서창희
2024Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease김유빈
2023Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis신성재
2014Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis박해심, 유혜수
2004Effect of Infliximab in the Treatment of Refractory Inflammatory Bowel Disease with Complication-
2023Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea신성재
2019Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study김현아
2023Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN)신성재
2016Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study신성재
2022Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 Era김유빈
2024Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease김유빈
2020Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis서창희
2021Impact of infliximab biosimilar ct-p13 dose and infusion interval on real-world drug survival and effectiveness in patients with ankylosing spondylitis서창희
2020Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry김현아
2020Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry김현아
2020Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry김현아
1

Browse